Literature DB >> 14517800

Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis.

Kazunori Shibao1, Keiji Hirata, Marie E Robert, Michael H Nathanson.   

Abstract

BACKGROUND AND AIMS: Cholestasis is one of the principal manifestations of liver disease and often results from disorders involving bile duct epithelia rather than hepatocytes. A range of disorders affects biliary epithelia, and no unifying pathophysiologic event in these cells has been identified as the cause of cholestasis. Here we examined the role of the inositol 1,4,5-trisphosphate receptor (InsP3R)/Ca(2+) release channel in Ca(2+) signaling and ductular secretion in animal models of cholestasis and in patients with cholestatic disorders.
METHODS: The expression and distribution of the InsP3R and related proteins were examined in rat cholangiocytes before and after bile duct ligation or treatment with endotoxin. Ca(2+) signaling was examined in isolated bile ducts from these animals, whereas ductular bicarbonate secretion was examined in isolated perfused livers. Confocal immunofluorescence was used to examine cholangiocyte InsP3R expression in human liver biopsy specimens.
RESULTS: Expression of the InsP3R was selectively lost from biliary epithelia after bile duct ligation or endotoxin treatment. As a result, Ca(2+) signaling and Ca(2+)-mediated bicarbonate secretion were lost as well, although other components of the Ca(2+) signaling pathway and adenosine 3',5'-cyclic monophosphate (cAMP)-mediated bicarbonate secretion both were preserved. Examination of human liver biopsy specimens showed that InsP3Rs also were lost from bile duct epithelia in a range of human cholestatic disorders, although InsP3R expression was intact in noncholestatic liver disease.
CONCLUSIONS: InsP3-mediated Ca(2+) signaling in bile duct epithelia appears to be important for normal bile secretion in the liver, and loss of InsP3Rs may be a final common pathway for cholestasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517800      PMCID: PMC2831084          DOI: 10.1016/s0016-5085(03)01201-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  64 in total

1.  The type II inositol 1,4,5-trisphosphate receptor can trigger Ca2+ waves in rat hepatocytes.

Authors:  Keiji Hirata; Thomas Pusl; Allison F O'Neill; Jonathan A Dranoff; Michael H Nathanson
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.

Authors:  Gianfranco Alpini; Leonardo Baiocchi; Shannon Glaser; Yoshiyuki Ueno; Marco Marzioni; Heather Francis; Jo Lynne Phinizy; Mario Angelico; Gene Lesage
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

Review 4.  Calcium signaling: a tale for all seasons.

Authors:  Ernesto Carafoli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

5.  Vesicular restriction of synaptobrevin suggests a role for calcium in membrane fusion.

Authors:  Kuang Hu; Joe Carroll; Sergei Fedorovich; Colin Rickman; Andrei Sukhodub; Bazbek Davletov
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

6.  Regulation of Ca(2+) signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms.

Authors:  Keiji Hirata; Jean-François Dufour; Kazunori Shibao; Roy Knickelbein; Allison F O'Neill; Hans-Peter Bode; Doris Cassio; Marie V St-Pierre; Nicholas F Larusso; M Fatima Leite; Michael H Nathanson
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

7.  Bile secretory function of intrahepatic biliary epithelium in the rat.

Authors:  G Alpini; R Lenzi; W R Zhai; P A Slott; M H Liu; L Sarkozi; N Tavoloni
Journal:  Am J Physiol       Date:  1989-07

8.  The C(2)B Ca(2+)-binding motif of synaptotagmin is required for synaptic transmission in vivo.

Authors:  J M Mackler; J A Drummond; C A Loewen; I M Robinson; N E Reist
Journal:  Nature       Date:  2002-07-07       Impact factor: 49.962

9.  An inositol 1,4,5-trisphosphate receptor-dependent cation entry pathway in DT40 B lymphocytes.

Authors:  Guillermo Vazquez; Barbara J Wedel; Gary St J Bird; Suresh K Joseph; James W Putney
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

Review 10.  Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Authors:  Gustav Paumgartner; Ulrich Beuers
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  50 in total

Review 1.  Role of lipid rafts in liver health and disease.

Authors:  Angela Dolganiuc
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma.

Authors:  Kazunori Shibao; Michael J Fiedler; Jun Nagata; Noritaka Minagawa; Keiji Hirata; Yoshifumi Nakayama; Yasuko Iwakiri; Michael H Nathanson; Koji Yamaguchi
Journal:  Cell Calcium       Date:  2010-11-13       Impact factor: 6.817

Review 3.  Calcium signaling in cholangiocytes.

Authors:  Noritaka Minagawa; Barbara-E Ehrlich; Michael-H Nathanson
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

4.  BG60S dissolution interferes with osteoblast calcium signals.

Authors:  P Valério; M M Pereira; A M Goes; M F Leite
Journal:  J Mater Sci Mater Med       Date:  2007-02       Impact factor: 3.896

5.  Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts.

Authors:  Marco Marzioni; Heather Francis; Antonio Benedetti; Yoshiyuki Ueno; Giammarco Fava; Juliet Venter; Ramona Reichenbach; Maria Grazia Mancino; Ryun Summers; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 6.  The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca²⁺-release channel.

Authors:  Tamara Vervloessem; David I Yule; Geert Bultynck; Jan B Parys
Journal:  Biochim Biophys Acta       Date:  2014-12-10

7.  Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference.

Authors:  Alphonse E Sirica; Michael H Nathanson; Gregory J Gores; Nicholas F Larusso
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

8.  Effects of Endotoxin on Type 3 Inositol 1,4,5-Trisphosphate Receptor in Human Cholangiocytes.

Authors:  Andressa Franca; Antonio Carlos Melo Lima Filho; Mateus T Guerra; Jittima Weerachayaphorn; Marcone Loiola Dos Santos; Basile Njei; Marie Robert; Cristiano Xavier Lima; Paula Vieira Teixeira Vidigal; Jesus M Banales; Meenakshisundaram Ananthanarayanam; M Fatima Leite; Michael H Nathanson
Journal:  Hepatology       Date:  2018-12-31       Impact factor: 17.425

9.  Inositol 1,4,5-trisphosphate receptor type 3 plays a protective role in hepatocytes during hepatic ischemia-reperfusion injury.

Authors:  Antônio Carlos Melo Lima Filho; Andressa França; Rodrigo M Florentino; Marcone Loiola Dos Santos; Fernanda de Oliveira Lemos; Dabny Goulart Missiaggia; Roberta Cristelli Fonseca; André Gustavo Oliveira; Meenakshisundaram Ananthanarayanan; Mateus T Guerra; Matheus de Castro Fonseca; Paula Vieira Teixeira Vidigal; Cristiano Xavier Lima; Michael H Nathanson; M Fatima Leite
Journal:  Cell Calcium       Date:  2020-08-11       Impact factor: 6.817

10.  Differentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation.

Authors:  Mario Strazzabosco; Romina Fiorotto; Saida Melero; Shannon Glaser; Heather Francis; Carlo Spirli; Gianfranco Alpini
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.